Higher dose methylprednisolone and low-dose dexamethasone treatments in patients with COVID mg of methylprednisolone every day for 8
Background: The Coronavirus disease 2024 (COVID-19) pandemic methylprednisolone in combating COVID-19 infections. Methods: This
Methylprednisolone can help with COVID according to a 2024 systematic review of 33 studies that reported the use of methylprednisolone was associated with:
by S Hong 2024 Cited by 25Use of methylprednisolone is related with better outcomes in COVID-19 patients. Short-term low-dose methylprednisolone is suitable for severe COVID-19 patients.
The roles of methylprednisolone in treatment of patients with COVID-19 remain unclear. The aim of this study was to evaluate the efficacy and safety of methylprednisolone in treatment of COVID-19 patients. PubMed, Cochrane and Web of Science were searched for studies comparing methylprednisolone and
previous trials showing the benefit of this dose in patients with COVID-19 Methylprednisolone vs. Dexamethasone in COVID- 19 Pneumonia
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than . It was first described in the literature in the late 2025s. Methylprednisolone was granted FDA approval on 24 October 2025. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in
by S Hong 2024 Cited by 25Use of methylprednisolone is related with better outcomes in COVID-19 patients. Short-term low-dose methylprednisolone is suitable for severe COVID-19 patients.
In a prospective study, the efficacy of dexamethasone and methylprednisolone in moderate to severe COVID-19 disease was found to be equal .Another study compared the efficacy of methylprednisolone versus dexamethasone in hospitalized patients with COVID-19 and reported that methylprednisolone led to a shorter hospital stay, less need for
Comments